U.S., Oct. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07862439) titled 'Biomarker-guided Reduction of Immunosuppression in Liver Transplant Recipients (BRITRE)' on Oct. 01.
Brief Summary: Researchers are interested in determining whether it is safe to reduce anti-rejection medication by approximately 50% after liver transplantation and whether special blood tests called biomarkers can identify early signs that the body is starting to attack the new liver before it gets hurt.
Study Start Date: Jan., 2027
Study Type: INTERVENTIONAL
Condition:
Liver Diseases
Intervention:
OTHER: miRNA Biomarker-Guided Immunosuppression Minimization
Participants undergo calcineurin inhibitor (CNI) dose reduction with ...